XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2

Segments (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Segment Profit

a. Segment information:

		Three months ended June 30,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,110			$	1,213			$	593
Gross profit			1,167				677				286
R&D expenses			170				62				30
S&M expenses			270				209				145
G&A expenses			100				64				38
Other income			(1	)			§				§
Segment profit		$	629			$	342			$	73

§ Represents an amount less than $0.5 million.

		Three months ended June 30,
		2023
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,892			$	1,163			$	578
Gross profit			1,017				640				283
R&D expenses			156				53				23
S&M expenses			250				194				125
G&A expenses			101				61				34
Other income			(1	)			(1	)			(31	)
Segment profit		$	511			$	334			$	132

		Six month ended June 30,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	3,835			$	2,485			$	1,190
Gross profit			2,025				1,415				583
R&D expenses			324				118				58
S&M expenses			530				403				263
G&A expenses			193				130				73
Other income			(1	)			§				(1	)
Segment profit		$	979			$	764			$	190

§ Represents an amount less than $0.5 million.

		Six month ended June 30,
		2023
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	3,569			$	2,347			$	1,159
Gross profit			1,806				1,294				568
R&D expenses			305				106				51
S&M expenses			457				381				238
G&A expenses			196				130				72
Other income			(1	)			(1	)			(33	)
Segment profit		$	850			$	679			$	240

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended June 30, 2024 and 2023:

		Three months ended June 30,								Six months ended June 30,
		2024				2023				2024				2023
		(U.S. $ in millions)								(U.S. $ in millions)
United States profit		$	629			$	511			$	979			$	850
Europe profit			342				334				764				679
International Markets profit			73				132				190				240
Total reportable segments profit			1,043				977				1,933				1,769
Profit (loss) of other activities			12				33				15				27
Total segments profit			1,056				1,011				1,948				1,796
Amounts not allocated to segments:
Amortization			146				162				298				326
Other assets impairments, restructuring and other items *			280				108				954				218
Goodwill impairment			400				700				400				700
Intangible assets impairments			61				63				141				241
Legal settlements and loss contingencies			83				462				188				695
Other unallocated amounts			91				170				190				282
Consolidated operating income (loss) *			(5	)			(654	)			(223	)			(667	)
Financial expenses, net			241				268				491				528
Consolidated income (loss) before income taxes *		$	(246	)		$	(923	)		$	(713	)		$	(1,195	)

* The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements.

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three months ended June 30, 2024 and 2023:

United States		Three months ended June 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	1,023			$	884
AJOVY®			42				52
AUSTEDO			407				308
BENDEKA® and TREANDA®			41				67
COPAXONE			81				56
Anda			373				392
Other			144				131
Total		$	2,110			$	1,892

United States		Six months ended June 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	1,831			$	1,631
AJOVY			87				98
AUSTEDO			689				478
BENDEKA and TREANDA			87				129
COPAXONE			111				127
Anda			754				816
Other			276				289
Total		$	3,835			$	3,569

Europe		Three months ended June 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	970			$	909
AJOVY			52				39
COPAXONE			53				60
Respiratory products			57				66
Other			81				89
Total		$	1,213			$	1,163

Europe		Six months ended June 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	1,974			$	1,841
AJOVY			102				74
COPAXONE			110				119
Respiratory products			123				134
Other			175				178
Total		$	2,485			$	2,347

International markets		Three months ended June 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	486			$	478
AJOVY			22				14
COPAXONE			14				17
Other			71				69
Total		$	593			$	578

International markets		Six months ended June 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	963			$	955
AJOVY			39				27
COPAXONE			25				34
Other			162				142
Total		$	1,190			$	1,159

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration